217 related articles for article (PubMed ID: 36503034)
1. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
Sullivan SD
Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
[TBL] [Abstract][Full Text] [Related]
2. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
3. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
4. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
5. The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.
Bhargava R; Brown N; Kapczynski A; Kesselheim AS; Lim SY; Morten CJ
J Law Med Ethics; 2023; 51(4):961-971. PubMed ID: 38477274
[TBL] [Abstract][Full Text] [Related]
6. Adjusting starting points for initial price offers: the example of ibrutinib.
Gibbons JB; Bennett CL; Carson KR; Anderson GF
Am J Manag Care; 2024 Apr; 30(4):193-196. PubMed ID: 38603534
[TBL] [Abstract][Full Text] [Related]
7. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
8. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
Johnson M; Kishore S; Nayak RK; Dusetzina SB
Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
[TBL] [Abstract][Full Text] [Related]
9. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
10. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
11. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
Vogel M; Kakani P; Chandra A; Conti RM
Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
[TBL] [Abstract][Full Text] [Related]
12. International Reference Pricing in the Context of US Drug Policy.
Frank R; Conti RM; Gruber J
J Health Polit Policy Law; 2022 Dec; 47(6):779-796. PubMed ID: 35867549
[TBL] [Abstract][Full Text] [Related]
13. Access in all areas? A round up of developments in market access and health technology assessment: part 2.
Beattie A; Treharne C; Mardiguian S; Ramagopalan SV
J Comp Eff Res; 2023 Dec; 12(12):e230162. PubMed ID: 37916681
[TBL] [Abstract][Full Text] [Related]
14. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; ():1-11. PubMed ID: 38905356
[TBL] [Abstract][Full Text] [Related]
15. Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries.
Rand LZ; Kesselheim AS
Pharmacoeconomics; 2022 Dec; 40(12):1131-1142. PubMed ID: 36348153
[TBL] [Abstract][Full Text] [Related]
16. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
17. The Problem of Limited-Supply Agreements for Medicare Price Negotiation.
Gabriele SME; Feldman WB
JAMA; 2023 Oct; 330(13):1223-1224. PubMed ID: 37713185
[TBL] [Abstract][Full Text] [Related]
18. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
Vogel M; Zhao O; Feldman WB; Chandra A; Kesselheim AS; Rome BN
JAMA Intern Med; 2024 Jan; 184(1):63-69. PubMed ID: 38010643
[TBL] [Abstract][Full Text] [Related]
19. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
20. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
Mueller MT; Frenzel A
Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]